Bicalutamide-activated oncolytic adenovirus for the adjuvant therapy of high-risk prostate cancer

Cancer Gene Therapy

Volumn 20, Issue 7, 2013, Pages 394-402

  Johnson, T J ^a   Hoti N ^a   Liu, C ^a   Chowdhury, W H ^a   Li, Y ^a   Zhang, Y ^b   Lupold, S E ^a,b   Deweese, T ^b   Rodriguez, R ^a,c  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b DEPARTMENT OF PATHOLOGY   (United States)

^c UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

Author keywords

Adenovirus; Anti androgen; CRAd; E1A ARC685Y; Fiber IRES GFP; Radiation

Indexed keywords

ANDROGEN; BICALUTAMIDE; COMPLEMENTARY DNA; ONCOLYTIC ADENOVIRUS;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER ADJUVANT THERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER RADIOTHERAPY; CELL DEATH; CODON; CONTROLLED STUDY; GENE THERAPY; HIGH RISK PATIENT; IN VITRO STUDY; LIGAND BINDING; MALE; MOUSE; NONHUMAN; POINT MUTATION; PRIORITY JOURNAL; PROSTATE CANCER; VIRUS REPLICATION;

ADENOVIRIDAE; AMINO ACID SUBSTITUTION; ANDROGEN ANTAGONISTS; ANILIDES; ANIMALS; CELL LINE, TUMOR; CELL SURVIVAL; COMBINED MODALITY THERAPY; HEK293 CELLS; HUMANS; MALE; MICE; MICE, INBRED BALB C; MICE, NUDE; NEOPLASM TRANSPLANTATION; NITRILES; ONCOLYTIC VIROTHERAPY; ONCOLYTIC VIRUSES; PROMOTER REGIONS, GENETIC; PROSTATIC NEOPLASMS; RECEPTORS, ANDROGEN; TOSYL COMPOUNDS; VIRAL ENVELOPE PROTEINS; VIRUS REPLICATION;

ADENOVIRIDAE;

EID: 84880922001     PISSN: 09291903     EISSN: 14765500     Source Type: Journal    
DOI: 10.1038/cgt.2013.34     Document Type: Article

References (26)

1. Petrylak DP. Chemotherapy for advanced hormone refractory prostate cancer. Urology 1999; 54: 30-35.
2. Petrylak DP, Tangen CM, Hussain MH, Lara Jr PN, Jones JA, Taplin ME et al. Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med 2004; 351: 1513-1520. (Pubitemid 39315318)
3. Kantoff P. Recent progress in management of advanced prostate cancer. Oncology 2005; 19: 631-636. (Pubitemid 350042593)
4. Berges RR, Vukanovic J, Epstein JI, CarMichel M, Cisek L, Johnson DE et al. Implication of cell kinetic changes during the progression of human prostatic cancer. Clin Cancer Res 1995; 1: 473-480.
5. Visakorpi T, Kallioniemi OP, Paronen IY, Isola JJ, Heikkinen AI, Koivula TA. Flow cytometric analysis of DNA ploidy and S-phase fraction from prostatic carcinomas: implications for prognosis and response to endocrine therapy. Br J Cancer 1991; 64: 578-582.
6. Spindler KR, Eng CY, Berk AJ. An adenovirus early region 1A protein is required for maximal viral DNA replication in growth-arrested human cells. J Virol 1985; 53: 742-750. (Pubitemid 15173276)
7. Greber UF, Willetts M, Webster P, Helenius A. Stepwise dismantling of adenovirus 2 during entry into cells. Cell 1993; 75: 477-486. (Pubitemid 23335073)
8. Gurnani M, Lipari P, Dell J, Shi B, Nielsen LL. Adenovirus-mediated p53 gene therapy has greater efficacy when combined with chemotherapy against human head and neck, ovarian, prostate, and breast cancer. Cancer Chemother Pharmacol 1999; 44: 143-151. (Pubitemid 29297061)
9. Shalev M, Kadmon D, Teh BS, Butler EB, Aguilar-Cordova E, Thompson TC et al. Suicide gene therapy toxicity after multiple and repeat injections in patients with localized prostate cancer. J Urol 2000; 163: 1747-1750. (Pubitemid 30366727)
10. Freytag SO, Khil M, Stricker H, Peabody J, Menon M, DePeralta-Venturina M et al. Phase I study of replication-competent adenovirus-mediated double suicide gene therapy for the treatment of locally recurrent prostate cancer. Cancer Res 2002; 62: 4968-4976. (Pubitemid 34984421)
11. Small EJ, Carducci MA, Burke JM, Rodriguez R, Fong L, van Ummersen L et al. A phase I trial of intravenous CG7870, a replication-selective, prostate-specific antigen-targeted oncolytic adenovirus, for the treatment of hormone-refractory, metastatic prostate cancer. Mol Ther 2006; 14: 107-117. (Pubitemid 43899483)
12. DeWeese TL, van der Poel H, Li S, Mikhak B, Drew R, Goemann M et al. A phase I trial of CV706, a replication-competent, PSA selective oncolytic adenovirus, for the treatment of locally recurrent prostate cancer following radiation therapy. Cancer Res 2001; 61: 7464-7472. (Pubitemid 32995035)
13. Hoti N, Li Y, Chen CL, Chowdhury WH, Johns DC, Xia Q et al. Androgen receptor attenuation of Ad5 replication: implications for the development of conditionally replication competent adenoviruses. Mol Ther 2007; 15: 1495-1503. (Pubitemid 47099307)
14. D'Amico AV, Schultz D, Loffredo M, Dugal R, Hurwitz M, Kaplan I et al. Biochemical outcome following external beam radiation therapy with or without androgen suppression therapy for clinically localized prostate cancer. JAMA 284: 1280-1283 2000.
15. Zapatero A, Garcia-Vicente F, Martin de Vidales C, Cruz Conde A, Ibanez Y, Fernandez I et al. Long-term results after high-dose radiotherapy and adjuvant hormones in prostate cancer: how curable is high-risk disease? Int J Radiat Oncol Biol Phys 2011; 81: 1279-1285.
16. Ceraline J, Erdmann E, Erbs P, Deslandres-Cruchant M, Jacqmin D, Duclos B et al. A yeast-based functional assay for the detection of the mutant androgen receptor in prostate cancer. Eur J Endocrinol 2003; 148: 99-110.
17. van der Poel HG, McCadden J, Verhaegh GW, Kruszewski M, Ferrer F, Schalken JA et al. A novel method for the determination of basal gene expression of tissue-specific promoters: an analysis of prostate-specific promoters. Cancer Gene Ther 2001; 8: 927-935. (Pubitemid 33140311)
18. Liu C, Zhang Y, Liu MM, Zhou H, Chowdhury W, Lupold SE et al. Evaluation of continuous low dose rate versus acute single high dose rate radiation combined with oncolytic viral therapy for prostate cancer. Int J Radiat Biol 2010; 86: 220-229.
19. Rodriguez R, Schuur ER, Lim HY, Henderson GA, Simons JW, Henderson DR. Prostate attenuated replication competent adenovirus (ARCA) CN706: a selective cytotoxic for prostate-specific antigen-positive prostate cancer cells. Cancer Res 1997; 57: 2559-2563. (Pubitemid 27283756)
20. Ryan CJ, Small EJ. The selection of hormonal therapy in prostate cancer: who, when, and for how long? J Natl Compr Canc Netw 2004; 2: 261-268.
21. Wu HC, Hsieh JT, Gleave ME, Brown NM, Pathak S, Chung LW. Derivation of androgen-independent human LNCaP prostatic cancer cell sublines: role of bone stromal cells. Int J Cancer 1994; 57: 406-412. (Pubitemid 24168617)
22. Reich NC, Sarnow P, Duprey E, Levine AJ. Monoclonal antibodies which recognize native and denatured forms of the adenovirus DNA-binding protein. Virology 1983; 128: 480-484. (Pubitemid 13048831)
23. Hoti N, Chowdhury WH, Mustafa S, Ribas J, Castanares M, Johnson T et al. Armoring CRAds with p21/Waf-1 shRNAs: the next generation of oncolytic adenoviruses. Cancer Gene Ther 2010; 17: 585-597.
24. Bolla M, Fourneret P, Beneyton V, Tessier A, Jover F, Verry C. [Combination of external irradiation and androgen suppression for prostate cancer: facts and questions]. Cancer Radiother 2010; 14: 510-514.
25. Han G, Buchanan G, Ittmann M, Harris JM, Yu X, Demayo FJ et al. Mutation of the androgen receptor causes oncogenic transformation of the prostate. Proc Natl Acad Sci USA 2005; 102: 1151-1156. (Pubitemid 40170741)
26. Waltering KK, Urbanucci A, Visakorpi T. Androgen receptor (AR) aberrations in castration-resistant prostate cancer. Mol Cell Endocrinol 2012; 360: 38-43.